Clinical Trials

Inclusion Criteria:

The inclusion criteria for this study are the following:

1. The patient must satisfy diagnostic criteria for at least one of the following diseases:
   1. Neuromyelitis optica spectrum disorders—Diagnostic criteria include history or evidence of optic neuritis and longitudinally extensive transverse myelitis without symptomatic involvement of the brain by history or MRI.
      1. NMO seropositive patients are those who have a circulating antibody, NMO-IgG, against aquaporin-4.
      2. NMO seronegative patients are those who likely have NMO but do not test positive for the NMO-IgG
      3. Any clinical syndrome associated with positive NMO-IgG
   2. Bilateral optic neuritis—Diagnostic criteria include history or evidence of optic neuritis in both eyes without symptomatic involvement of the brain by history.
   3. Longitudinally extensive transverse myelitis—Diagnostic criteria include history or evidence of longitudinally extensive inflammation across at least three continuous vertebral lengths of the spinal cord without symptomatic involvement of the brain by history or MRI.
   4. Recurrent transverse myelitis—Diagnostic criteria include history or evidence of inflammation in the spinal cord that recurred at least 3 months apart with evidence of remission in between events.
   5. Monophasic transverse myelitis—Diagnostic criteria include history of evidence of inflammation in one focal area of the spinal cord without recurrence or symptomatic involvement of the brain by history or MRI.